Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients’ prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. H...

Full description

Bibliographic Details
Main Authors:	Marco Russano, Giulia La Cava, Alessio Cortellini, Fabrizio Citarella, Alessandro Galletti, Giuseppina Rita Di Fazio, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Iacopo Fioroni, Francesco Pantano, Giuseppe Tonini, Bruno Vincenzi
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Current Oncology
Subjects:	immunotherapy non-small cell lung cancer immune checkpoint inhibitors PD-1/PD-L1 antibodies combination strategies biomarkers
Online Access:	https://www.mdpi.com/1718-7729/30/2/181

Similar Items

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

The Role of Immunotherapy in Pancreatic Cancer
by: Reetu Mukherji, et al.
Published: (2022-09-01)

Intestinal microbiota: a new force in cancer immunotherapy
by: Zhujiang Dai, et al.
Published: (2020-06-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Real Impact of Novel Immunotherapy Drugs in Cancer. The Experience of 10 Last Years
by: Andreas Koulouris, et al.
Published: (2021-02-01)

Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
by: Yuzhen Qian, et al.
Published: (2024-03-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
by: Xingxiang Pu, et al.
Published: (2018-11-01)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
by: Xianjing Chu, et al.
Published: (2023-06-01)

Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy
by: Yuyu Zheng, et al.
Published: (2020-07-01)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
by: Georges Gebrael, et al.
Published: (2023-01-01)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
by: Adel Naimi, et al.
Published: (2022-04-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
by: Zhanjun Guo, et al.
Published: (2022-03-01)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
by: Roman Groisberg, et al.
Published: (2017-12-01)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
by: Tao Wang, et al.
Published: (2022-05-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
by: Hao Liu, et al.
Published: (2019-10-01)

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers
by: Virginia Liberini, et al.
Published: (2021-04-01)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
by: Giuseppe Luigi Banna, et al.
Published: (2020-07-01)

Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer
by: Koichi Furukawa, et al.
Published: (2020-08-01)

PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
by: Weijia Huang, et al.
Published: (2022-10-01)

Immunotherapy using PD‑1/PDL-1 inhibitors in triple‑negative breast cancer: a systematic review
by: Dione Tavares, et al.
Published: (2021-12-01)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
by: Mengjie Wang, et al.
Published: (2022-04-01)

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
by: Seyed Hossein Kiaie, et al.
Published: (2023-09-01)

Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
by: Zin W. Myint, et al.
Published: (2017-04-01)

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
by: Chongxian Pan, et al.
Published: (2020-04-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Enhancing cancer care with improved checkpoint inhibitors
by: Vickram A S, et al.
Published: (2024-10-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

On Demand Biosensors for Early Diagnosis of Cancer and Immune Checkpoints Blockade Therapy Monitoring from Liquid Biopsy
by: Sai Mummareddy, et al.
Published: (2021-12-01)

Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
by: Kazuhiko Hashimoto, et al.
Published: (2020-07-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)

Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
by: Joe Yeong, et al.
Published: (2019-02-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
by: Federica Costa, et al.
Published: (2018-09-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
by: Rola El Sayed, et al.
Published: (2021-10-01)

Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
by: Vida Vafaizadeh, et al.
Published: (2020-03-01)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
by: Doris Helbig, et al.
Published: (2022-11-01)